ZYME

26.6800.67%
KH

Kenneth H. Galbraith

Chairman of the Board, CEO & President

Mr. Kenneth H. Galbraith, C.A., also known as Ken, is a Director of AudienceView Ticketing Corporation. He serves as Chairman of Zomp Group Ltd. He is Director of NeurAxon Inc. He served as Acting Chief Financial Officer at Zymeworks Inc. since 2026 until April 01, 2026. He is CEO & Chairman of the Board of Zymeworks Inc. since January 15, 2022 and serves as its President since June 2023. Mr. Galbraith served as zymeInterim CFO from 2024 to September 1, 2024. He has served as an advisor to SIML since May 2023 and as a director of SIML since November 2024, including as Chair since February 2025. He was President of Zymeworks Inc. from January 15, 2022 to August 04, 2022. He is Director of Zymeworks Inc. He serves as an Executive Partner at Syncona Investment Management Limited and served as a Director at the firm. He was Managing Partner of Syncona Investment Management Limited from 2023. He was an Executive in Residence of Syncona Investment Management Limited from April 2021. He was Independent Director of MacroGenics, Inc. from July 2008 to January 05, 2022. He was employed at MacroGenics, Inc. from July 2008 to January 05, 2022. He was Director of Angiotech Pharmaceuticals Inc. He joined the Angiotech Pharmaceuticals Inc. in March 2000. He was Director of Lundbeck Seattle BioPharmaceuticals, Inc. He was Chief Financial Officer and Executive Vice President of Novelion Therapeutics Inc. He was Chairman of TRACON Pharmaceuticals, Inc. He was employed at TRACON Pharmaceuticals, Inc. from December 06, 2011 to May 2014. He was Director of Neoleukin Therapeutics, Inc. He was Director of Allon Therapeutics Inc. He joined the Allon Therapeutics Inc. in 2001. He was Director of Correvio Pharma Corp. He joined the Correvio Pharma Corp. on May 12, 2003. He was Independent Director of Profound Medical Corp. from January 17, 2017 to May 17, 2023. He was employed at Profound Medical Corp. from January 17, 2017 to May 17, 2023. He was Independent Director of Arbutus Biopharma Corporation. He was employed at Arbutus Biopharma Corporation from January 28, 2010 to August 22, 2014. He was Director of Celator Pharmaceuticals, Inc. He was employed at Celator Pharmaceuticals, Inc. from 2008 to October 2013. He was CEO & Director of Liminal BioSciences Inc. from April 23, 2019 to November 13, 2020. He was Independent Director of Liminal BioSciences Inc. from 2016 to April 23, 2019. He was employed at Liminal BioSciences Inc. from August 10, 2016 to November 13, 2020. He was Director of Nventa Biopharmaceuticals Corporation. He joined the Nventa Biopharmaceuticals Corporation in May 2000. He was Chairman of the Board of Active Pass Pharmaceuticals Inc. He joined the Active Pass Pharmaceuticals Inc. in October 1999. He was Executive Chairman and Interim Chief Executive Officer of AnorMED Inc. He joined the AnorMED Inc. on April 21, 2006. He was Director of Kinetek Pharmaceuticals, Inc. He was Director of Metro Vancouver Properties Corp. He was employed at Metro Vancouver Properties Corp. until September 18, 2004. He was Member of the Board of Directors of Genome British Columbia. He was Chairman of Presidio Pharmaceuticals, Inc. He joined the Presidio Pharmaceuticals, Inc. on August 29, 2007. He was General Partner of Ventures West Capital Ltd. He joined the Ventures West Capital Ltd. in 2007. He focused on Biotech and Life Sciences. He was Managing Director of Five Corners Capital Inc., which he founded in 2013, from February 2021 until January 2022. He has many years of experience in biotechnology and venture capital. He has worked as a CEO, CFO, Executive Chair, Director, Investor and advisor across North America in the growth of both private and NASDAQ-listed companies from an early-stage through commercialisation. He has many years of experience in the management of venture capital funds and new company formation. He worked at Alder Pharmaceuticals, Novadaq, Fairhaven Pharmaceuticals, Tekmira and Aquinox. He serves as a Non-Executive Chair at Kalium Health. He began his career in 1987 as Chief Financial Officer at QLT, where he was instrumental in growing it to over 500 employees, gaining market approvals for several new medicines and achieving peak market capitalisation at the time of his departure in 2000. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. He has B. Com. from The University of British Columbia in 1985.

Positions